Biora Therapeutics, Inc. PROG
Set alert
At close
52-week range unavailable
- Open
- 0.9005
- Prev close
- 0.8845
- Mkt cap
- 162.92M
- Vol
- 2.78M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.84
- High
- 0.92
- Forward P/E
- -2.39
- Beta
- 0.00
- Short ratio
- 0.00
- Inst. own
- 29.78%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 10, 2022
- 50-d avg
- 1.07
- 200-d avg
- 1.78
- 1y target
- 4.00
Key statistics
- Market cap
- 162.92M
- Enterprise value
- 192.65M
- Trailing P/E
- 0.00
- Forward P/E
- -2.39
- PEG ratio
- 0.00
- Price / sales
- 130.65
- Price / book
- 0.00
- EPS (TTM)
- -2.57
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.25M
- Revenue growth
- 310.40%
- Free cash flow
- -52.35M
- Total cash
- 88.40M
- Total debt
- 126.89M
- Return on equity
- 0.00%
- Shares outstanding
- 184.20M
- Short % of float
- 0.00%
- 50-day average
- 1.07
- 200-day average
- 1.78
Analyst view
Consensus: strong buy
Next earnings
May 10, 2022
Expected May 10, 2022. Consensus EPS estimate -0.12.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 10, 2022 | Mar 1, 2022 | -0.12 | — | — | — |
| Mar 28, 2022 | Dec 1, 2021 | -0.13 | — | — | — |
| Nov 10, 2021 | Sep 1, 2021 | -0.47 | — | — | — |
| Aug 12, 2021 | Jun 1, 2021 | -0.80 | — | — | — |
| May 13, 2021 | Mar 1, 2021 | -0.83 | — | — | — |
| Mar 18, 2021 | Dec 1, 2020 | -0.76 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2021 | HC Wainwright & Co. | init | — | Buy |
| Jun 3, 2021 | Raymond James | down | Outperform | Market Perform |
| Jun 3, 2021 | Baird | down | Outperform | Neutral |
| May 17, 2021 | Wells Fargo | main | — | Underweight |
| May 14, 2021 | Raymond James | main | — | Outperform |
| Feb 8, 2021 | Wells Fargo | down | Overweight | Underweight |
About Biora Therapeutics, Inc.
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
- Country
- United States
- Website
- progenity.com
News
- Progenity Announces Successful Transfer of Liquid Biopsy Technologies
- 81 Biggest Movers From Yesterday
- Progenity Appoints Paul Shabram to Lead Technical Operations of the Company's Ingestible Drug/Device Platforms
- Progenity to Become Biora Therapeutics as it Completes Transformation
- Progenity Announces Two Poster Presentations at Controlled Release Society 2022
- Progenity, Inc. (PROG) CEO Adi Mohanty on Q4 2021 Results - Earnings Call Transcript
- Progenity Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
- Should You Invest in These Penny Stocks Next Month? 3 to Watch
- Penny Stocks To Buy Now? 4 Short Squeeze Stocks To Watch This Week
- Progenity to Report Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update
Your note
Sign in to keep a note on PROG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ATHYRIUM OPPORTUNITIES FUND A, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 13, 2021 | 0 |
| BIGALKE JOHN T | Director | Stock Award(Grant) | Jun 13, 2021 | 47,518 |
| D'ESPARBES ERIC | Chief Financial Officer | Stock Award(Grant) | Apr 14, 2022 | 423,171 |
| HOWE JILL ANN | Director | Stock Award(Grant) | Nov 2, 2021 | 76,754 |
| KOTZIN BRIAN L | Director | Stock Award(Grant) | Jun 13, 2021 | 47,518 |
| MOHANTY ADITYA P | Chief Executive Officer | Stock Award(Grant) | Nov 7, 2021 | 1,412,430 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Athyrium Capital Management, LP | 16.21% | 29,855,847 | 62.40M | Dec 30, 2021 |
| Neuberger Berman Group, LLC | 3.55% | 6,541,060 | 7.59M | Mar 30, 2022 |
| Vanguard Group, Inc. (The) | 2.80% | 5,155,896 | 5.98M | Mar 30, 2022 |
| Blackrock Inc. | 0.90% | 1,662,082 | 1.93M | Mar 30, 2022 |
| Geode Capital Management, LLC | 0.63% | 1,153,411 | 1.34M | Mar 30, 2022 |
| Susquehanna International Group, LLP | 0.52% | 955,317 | 1.11M | Mar 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.64% | 3,025,977 | 6.32M | Dec 30, 2021 |
| Vanguard Extended Market Index Fund | 0.86% | 1,575,406 | 3.29M | Dec 30, 2021 |
| Fidelity Extended Market Index Fund | 0.33% | 615,326 | 830.69K | Feb 27, 2022 |
| Fidelity Total Market Index Fund | 0.11% | 210,765 | 284.53K | Feb 27, 2022 |
| Fidelity Series Total Market Index Fund | 0.07% | 121,330 | 163.79K | Feb 27, 2022 |
| Fidelity NASDAQ Composite Index Fund | 0.04% | 80,797 | 109.08K | Feb 27, 2022 |